Apimeds Pharmaceuticals appoints Sungjoon Chae as Co-CEO

Apimeds Pharmaceuticals US, Inc.

Sungjoon Chae appointed Co-CEO effective May 4, 2026, pursuant to a stockholder nomination.
No family relationships or related party transactions with company officers or directors.
Compensation terms for Chae have not yet been determined; will be disclosed when finalized.
Chae holds a Master of Architecture in Urban Design from Harvard University and specializes in large-scale real estate and urban regeneration.
Existing CEO Dr. Vin Menon continues as CEO; Chae serves as Co-CEO.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Sungjoon Chae

Co-Chief Executive Officer

APUS · Apimeds Pharmaceuticals US, Inc.

Effective: 2026-05-04
Filed: May 5, 2026, 7:59 PM ET

On May 4, 2026, pursuant to a nomination by a stockholder of Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the " Company "), the board of directors of the Company (the " Board ") appointed Sungjoon Chae to serve as Co-Chief Executive Officer of the Company, effective as of such date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sungjoon Chae was appointed as Co-Chief Executive Officer at Apimeds Pharmaceuticals US, Inc..

Action: appointed
Role: Co-Chief Executive Officer

Exact text from the filing

On May 4, 2026, pursuant to a nomination by a stockholder of Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the " Company "), the board of directors of the Company (the " Board ") appointed Sungjoon Chae to serve as Co-Chief Executive Officer of the Company, effective as of such date.

View on SEC.gov

Apimeds Pharmaceuticals US, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-052036

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.